fergus0123
Posted - 5 days ago
$KALV does this company have any approved drugs? Looking for something other than bcrx to invest in.
UBER_ONE
Posted - 1 week ago
$PRZO $KALV MM Alert Patent listed $XCUR
FonsieTrader
Posted - 1 week ago
Calling it now: $WNW poised to be the next $KALV! Mark this post! Similar setup, explosive potential! Keep a close watch!
BioGem
Posted - 2 weeks ago
$KALV Another significant reason as to why the stock is expected to struggle, and why it is so heavily shorted is the news below from Pharvaris. The addressable market is already quite small for the on-demand (as many patients will receive prophylaxis and rarely use the 'as needed' drug); add the stiff competition and you can see how sales are expected to be sluggish.
Carlito84
Posted - 2 weeks ago
$KALV $20 soon
Marconzi
Posted - 3 weeks ago
$KALV 40+ coming. Insane. I know
Stock_Titan
Posted - 3 weeks ago
$KALV KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-to-present-at-23rd-annual-needham-virtual-yn31ijevgnqw.html
Stock_Titan
Posted - 3 weeks ago
$KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-reports-inducement-grants-under-nasdaq-uigpednfmcb4.html
waterlock
Posted - 3 weeks ago
$KALV WTF?!!? I did not notice this. They have closed 150M USD at ~$15. I thought their stock price went to so did not completed he fundraising. Well, now it is a huge buy for me. ================= Also in February, KalVista closed an underwritten offering to sell an aggregate of 7,016,312 shares of common stock at price of $15.25 per share and pre-funded warrants to purchase up to 3,483,688 shares of common stock at a price of $15.249 per pre-funded warrant. Top 3 holding: $MGTX $SANA $KALV
_StockTrader
Posted - 03/28/24
Real-Time Stock Data $KALV
Price: 12.21
Volume: 1718465
Market Cap: 513009728
PE Ratio: -4.9836063
Powered by: AITX
Alexander_Grothendieck
Posted - 03/28/24
$KALV Someone bought 1M shares right at the open. No news. Maybe BO?
Friesenkoei
Posted - 03/28/24
$KALV why?
BioGem
Posted - 1 month ago
$KALV I took a short position in the mid 11's because: -Expectation is for 200M in cash by April 2024, with a burn of 25-30M per Q, while it will increase for commercial preparation, I can see them running low on cash by early 2025, even before approval. -The main issue is the development lately of preventative medications for HAE that can be given very sporadically, which will make their market quite small. -Thus, it will take a few years before any profitability, while expenses will be large. -No large, specialized biotech funds are in, which means they don't see the value at this price. -Short interest is high = consensus of poor stock performance.
waterlock
Posted - 1 month ago
$KALV market cap is easy to loose. This is an obvious but. I'm in for more
StockInvest_us
Posted - 1 month ago
Signal alert: $KALV - Oversold Trend Short (Undervalued) https://stockinvest.us/l/FDNVeDXaCO
briefingcom
Posted - 1 month ago
$KALV: KalVista Pharmaceuticals presents real-world data on burden of treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240318063441KALV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
G101SPM
Posted - 1 month ago
$KALV $11.93 last bid. DAC $12.58 (1.18.24). EXIT $25.00* * Beyond March 18, 2025. UPDATE : KalVista Pharmaceuticals presents positive real-world data on burden of treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas .
Stock_Titan
Posted - 1 month ago
$KALV KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-presents-real-world-data-on-burden-of-y7n5qq57x2gj.html
G101SPM
Posted - 1 month ago
$KALV $13.10 last. DAC $12.58 (1.18.24. EXIT $25.00. UPDATE: Today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). The PIM is the first step in the Early Access to Medicines Scheme (EAMS) which would allow KalVista to treat patients with sebetralstat prior to receiving a Marketing Authorisation.
Stock_Titan
Posted - 1 month ago
$KALV KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-awarded-uk-promising-innovative-medicine-4p8abnp058al.html
Tyronavirus
Posted - 1 month ago
$KALV I thought ER was tomorrow?
epsguid
Posted - 1 month ago
$KALV reported a loss of $0.84, consensus was ($0.75) via @eWhispers #epsmiss http://eps.sh/d/kalv
DonCorleone77
Posted - 1 month ago
$KALV KalVista reports Q3 EPS (84c), consensus (77c) Reports Q3 revenue $0 vs. $0 last year. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and the completion of a substantial financing," said Ben Palleiko, Chief Executive Officer of KalVista. "We remain on track to file the NDA with the U.S. Food and Drug Administration in the first half of this year, and we look forward to presenting further phase 3 data for sebetralstat at upcoming patient and medical meetings. We also continue to grow the commercial organization to enable us to deliver on the promise of providing the first oral, on-demand treatment option to the HAE community."
G101SPM
Posted - 1 month ago
$KALV $14.36 close. DAC (dollar average cost) $12.58 (1.18.24). EXIT $25.00 Retain position. UPDATE: Reports Q3 EPS of ($0.84) vs ($0.75) FactSet consensus; co reported no revs, as expected. Cash Position: Cash, cash equivalents and marketable securities were $75.6 million as of January 31, 2024, compared to $149.4 million as of April 30, 2023. note: From report --- "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and the completion of a substantial financing,” said Ben Palleiko, Chief Executive Officer of KalVista. “We remain on track to file the NDA with the FDA in the first half of this year, and we look forward to presenting further phase 3 data for sebetralstat at upcoming patient and medical meetings."
Stock_Titan
Posted - 1 month ago
$KALV KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-reports-third-fiscal-quarter-results-and-tdwawsu6me7g.html
Stock_Titan
Posted - 1 month ago
$KALV KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-to-present-hae-attack-journey-data-at-2024-2b4zhedv0wa4.html
G101SPM
Posted - 1 month ago
$KALV $14.378 last. DAC (dollar average cost) $12.58. EXIT $25.00. NEWS: Co announced that Benjamin L. Palleiko, the Company's current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the KONFIDENT Phase 3 trial for its program sebetralstat as the first potential oral, on-demand therapy for hereditary angioedema (HAE), with a planned US NDA filing in the first half of this year.
G101SPM
Posted - 1 month ago
$KALV $13.98 last. DAC $12.58 (1.18.24). EXIT $25.00. UPDATE: Today announced that its management will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12th, 2024 at 9:20 a.m. ET in Miami, FL.
Stock_Titan
Posted - 1 month ago
$KALV KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
https://www.stocktitan.net/news/KALV/kal-vista-pharmaceuticals-to-participate-in-the-leerink-partners-atz5vvpq1t7f.html